The Latest Nuclear Medicine Image for Biochemically Recurrent Prostate Cancer—AXUMINⓇ PET


The incidence of prostate cancer has been rapidly increasing in the past decades in Taiwan. It became the fifth common cancer in Taiwanese males.  AXUMIN Injection is a radiopharmaceutical, indicated for patients with suspected biochemically recurrent prostate cancer. AXUMIN PET image is able to precisely detected local lesions as well as distance metastasis, which assists clinical physicians to select adequate therapy programs for patients with prostate cancer recurrence.




The traditional imaging modalities ( CT、MRI or 18F-FDG PET) for recurrent prostate cancer have their limitations.  Those are not reliable in detecting early stage of local failure and/or distant metastasis.  Axumin PET has much higher sensitivity and detection rate.




The image of AXUMIN PET provides clear information about sites of disease recurrence. This allows clinical physicians (urologists and/or oncologists) to create appropriate treatment plan and avoid unnecessary therapies.




AXUMIN PET is a noninvasive diagnostic modality and is convenient for patients and imaging facilities, as it can be made widely available.  The entire imaging procedure can typically be completed in less than 30 minutes.




Booth No.M331a